# Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

> **NCT00002099** · PHASE2 · UNKNOWN · sponsor: **AJI Pharma USA**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lentinan
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002099
- **Lead sponsor:** AJI Pharma USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002099, "Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00002099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*